Ohmura Yoshiaki, Takeda Yutaka, Nagano Hiroaki, Nakamori Shoji, Kobayashi Shogo, Marubashi Shigeru, Eguchi Hidetoshi, Tanemura Masahiro, Kitagawa Toru, Monden Morito, Mori Masaki, Doki Yuichiro
Department of Surgery, Graduate School of Medicine, Osaka University, and Osaka National Hospital, National Hospital Organization.
Gan To Kagaku Ryoho. 2009 Nov;36(12):2428-9.
A 69-year-old man with chief complaint of epigastralgia was diagnosed as locally advanced borderline unresectable pancreatic head cancer that involved superior membrane artery (SMA). Gemcitabine (GEM) -based chemoradiotherapy (CRT) was administered for consecutive 3 weeks in the following fashion: continuous twice-a-day accelerated radiotherapy (2 daily fractions of 1.5 Gy, 5 days a week, with a 6-hr minimal interval between fractions) with 3-time weekly intravenous infusions of GEM. Total radiation dose was 45 Gy and GEM was given on days 1, 8 and 15 at dose of 800 mg/m2. After the completion of CRT, the involvement of SMA remained. Next, additional systemic chemotherapy with GEM was performed for 3 weeks in the following fashion: weekly intravenous infusions of GEM at dose of 1,000 mg/m2. Finally, the main tumor and the invasion to SMA were reduced. Surgical resection with negative margins (R0 resection) was performed. Adjuvant chemotherapy with 6 courses of GEM was also performed. The patient has no recurrence, suggesting the efficacy of GEM-based CRT for locally advanced borderline unresectable pancreatic cancer.